Drug Discovery
By
Can Catalio Capital’s $400 Million AI-Driven Life Sciences Fund Ignite a New Era of Biomedical Innovation Despite a Slow VC Market?
Key Takeaways Resilience in a Cooling VC ClimateCatalio Capital Management has successfully closed its fourth Nexus Fund at…
Is Portal Biotech’s $35M Series A Set to Redefine Proteomics With the World’s First AI-Powered Full-Length Single-Molecule Protein Sequencer?
Key Takeaways Transforming Protein Sequencing With AI and Nanopore InnovationPortal Biotech, a London-based pioneer in proteomics, is aiming…
How Is XtalPi’s Expanded Collaboration With Pfizer Set to Transform AI-Driven Small Molecule Drug Discovery?
Key Takeaways Empowering Next-Gen AI Platforms for Predictive Drug DiscoveryXtalPi and Pfizer have extended their strategic partnership to…
Is AI-Engineered HMBD-002 the Next Big Immunotherapy? Hummingbird Bioscience Signs $290M Global Licensing Deal with Percheron Therapeutics
Key Highlights Strategic Global Licensing Deal Hummingbird Bioscience has signed a worldwide licensing agreement with Percheron Therapeutics for…
Could AbbVie and IGI’s $1.9B Bet on AI-Engineered Trispecific Antibody Signal a New Era for Relapsed Myeloma Treatment?
Key Highlights: AbbVie Accelerates into AI-Powered Immuno-OncologyAbbVie has entered a global licensing agreement worth up to $1.925 billion…
Will AI-Powered Querent™ by Mango Sciences Transform Veeda Lifesciences’ Global Clinical Trial Efficiency?
Key Highlights AI-Driven Precision in Global Trial RecruitmentVeeda Lifesciences, a global CRO, has announced a strategic investment in…
